Volastra unveils first human data of its solid tumor drug target

ASCO25: Volastra announces first-in-human data for KIF18A inhibitor

Volastra will be presenting the preliminary data from the Phase I/II trial of its KIF18A inhibitor during ASCO 2025.The post ASCO25: Volastra announces first-in-human data for KIF18A inhibitor appeared first on Clinical Trials Arena.

Volastra unveils first human data of its solid tumor drug target

Volastra Therapeutics has been bullish about KIF18A as a solid tumor drug target. And now, more than five years after launch, the company is reporting first human data from its in-house drug, VLS-1488. First findings ...